EdiGENE Corporation is an emerging biotech company focusing on developing transformative therapeutics for unmet medical needs using its proprietary technologies on CRISPR and protein engineering platforms. The company has a strong foundation on intellectual property licensed from the University of Tokyo.
Our mission is to deliver novel therapeutics for diseases which are caused by malfunctioning of genes, and yet cannot be managed, treated or cured with existing therapeutic modalities. We aspire to make un-druggable targets druggable.
EdiGENE Corporation is headquartered in Tokyo Japan, with main operations conducted at EdiGENE Inc. in Cambridge MA, USA, a heart of innovation for biomedical science.